CN108884053B - 预防和/或治疗与衰老有关的认知障碍和神经炎症的方法 - Google Patents

预防和/或治疗与衰老有关的认知障碍和神经炎症的方法 Download PDF

Info

Publication number
CN108884053B
CN108884053B CN201680079142.9A CN201680079142A CN108884053B CN 108884053 B CN108884053 B CN 108884053B CN 201680079142 A CN201680079142 A CN 201680079142A CN 108884053 B CN108884053 B CN 108884053B
Authority
CN
China
Prior art keywords
medicament
subject
neuroinflammation
animals
microglia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680079142.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN108884053A (zh
Inventor
K·D·恩古彦
E·G·英格利曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CN108884053A publication Critical patent/CN108884053A/zh
Application granted granted Critical
Publication of CN108884053B publication Critical patent/CN108884053B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Hydrogenated Pyridines (AREA)
CN201680079142.9A 2015-12-15 2016-12-09 预防和/或治疗与衰老有关的认知障碍和神经炎症的方法 Active CN108884053B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562267437P 2015-12-15 2015-12-15
US62/267,437 2015-12-15
PCT/US2016/065972 WO2017106050A1 (en) 2015-12-15 2016-12-09 Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation

Publications (2)

Publication Number Publication Date
CN108884053A CN108884053A (zh) 2018-11-23
CN108884053B true CN108884053B (zh) 2022-01-04

Family

ID=59057428

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680079142.9A Active CN108884053B (zh) 2015-12-15 2016-12-09 预防和/或治疗与衰老有关的认知障碍和神经炎症的方法

Country Status (18)

Country Link
US (3) US10653669B2 (enExample)
EP (2) EP3390367B1 (enExample)
JP (1) JP6837486B2 (enExample)
KR (1) KR20180094989A (enExample)
CN (1) CN108884053B (enExample)
AU (1) AU2016371598B2 (enExample)
CA (1) CA3008019A1 (enExample)
DK (1) DK3390367T3 (enExample)
ES (1) ES2830447T3 (enExample)
HR (1) HRP20201652T1 (enExample)
HU (1) HUE051771T2 (enExample)
IL (2) IL285248B2 (enExample)
MX (1) MX379086B (enExample)
PL (1) PL3390367T3 (enExample)
PT (1) PT3390367T (enExample)
RS (1) RS61053B1 (enExample)
SM (1) SMT202000601T1 (enExample)
WO (1) WO2017106050A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016061190A1 (en) 2014-10-14 2016-04-21 The Board Of Trustees Of The Leland Stanford Junior University Method for treating neurodegenerative diseases
KR20180094989A (ko) * 2015-12-15 2018-08-24 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 주니어 유니버시티 노화 관련 인지장애 및 신경염증의 예방 및/또는 치료 방법
IL280664B2 (en) 2018-08-06 2023-04-01 Univ Leland Stanford Junior 2-Arylbenzimidazoles as ppargc1a stimulators for the treatment of neurodegenerative diseases
EP4171551A1 (en) 2020-06-22 2023-05-03 Tranquis Therapeutics, Inc. Treatment of systemic immune activation syndromes
CN112933232A (zh) * 2021-02-02 2021-06-11 袁玉佳 PGC-1α激活TFEB介导的自噬在制备治疗急性肾损伤的药物中的应用
US20240307356A1 (en) * 2021-06-17 2024-09-19 Tranquis Therapeutics, Inc. Therapeutically effective oral administration of a 2 arylbenzimidazole
US20250009714A1 (en) 2021-11-02 2025-01-09 Tranquis Therapeutics, Inc. Selection and treatment of subjects having a circulating myeloid cell inflammatory phenotype
TW202415372A (zh) 2022-06-14 2024-04-16 美商特朗奎斯治療股份有限公司 老化相關改變及疾病之治療
TW202416960A (zh) 2022-06-17 2024-05-01 美商特朗奎斯治療股份有限公司 2-芳基苯并咪唑化合物之調配物
AU2023380184A1 (en) * 2022-11-18 2025-07-03 Satoshi Gojo Uses of zln-005 and related compounds
WO2024118936A1 (en) 2022-12-02 2024-06-06 Tranquis Therapeutics, Inc. 2-arylbenzimidazole compounds for the treatment of hemoglobinopathies

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4188486A (en) * 1976-12-07 1980-02-12 Kanebo, Ltd. 2-Substituted benzimidazole compounds
WO2003004023A1 (de) * 2001-07-06 2003-01-16 Schering Aktiengesellschaft 1-alkyl-2-aryl-benzimidazolderivate, deren verwendung zur herstellung von arzneimitteln sowie diese derivate enthaltende pharmazeutische präparate
CN1395568A (zh) * 2000-01-14 2003-02-05 舍林股份公司 用于治疗与小胶质细胞活化有关的疾病的1,2－二芳基苯并咪唑衍生物
WO2004000817A2 (en) * 2002-06-24 2003-12-31 Pfizer Products Inc. Benzimidazole compounds and their use as estrogen agonists/antagonists
CN1756546A (zh) * 2002-02-15 2006-04-05 舍林股份公司 用于阻断白细胞介素12和IFNγ介导的免疫反应的小胶质细胞抑制剂
CN101083985A (zh) * 2004-09-21 2007-12-05 幸讬制药公司 用于炎症及免疫相关用途的化合物
CN101142194A (zh) * 2005-03-14 2008-03-12 特兰斯泰克制药公司 吲哚衍生物，组合物及用作β-分泌酶抑制剂的方法
CN104873500A (zh) * 2015-04-29 2015-09-02 中国人民解放军第四军医大学 化合物zln005的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53127475A (en) * 1977-04-07 1978-11-07 Kanebo Ltd Novel benzimidazole compound and its preparation
NZ222495A (en) 1986-11-21 1991-04-26 Haessle Ab Benzimidazole derivatives and pharmaceutical compositions
US5552426A (en) * 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide
ATE284392T1 (de) 1998-11-03 2004-12-15 Abbott Gmbh & Co Kg Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung
SE0301371D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab New Compounds
NZ552093A (en) * 2004-06-17 2009-06-26 Wyeth Corp Processes for preparing gonadotropin releasing hormone receptor antagonists
US7689227B2 (en) * 2005-03-02 2010-03-30 Qualcomm Incorporated Method and apparatus for hashing over multiple frequency bands in a communication system
US20070037865A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
GB0807103D0 (en) 2008-04-18 2008-05-21 Univ Bradford The Compounds
GB201009656D0 (en) 2010-06-09 2010-07-21 Univ St Andrews Carboxylation catalysts
AU2013250726B2 (en) 2012-04-20 2017-01-05 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
KR101435496B1 (ko) 2012-10-22 2014-08-28 한국과학기술연구원 미토콘드리아 기능 조절제로서의 벤즈이미다졸 유도체
US10022357B2 (en) * 2013-04-29 2018-07-17 The General Hospital Corporation Amyloid precursor protein MRNA blockers for treating Down syndrome and Alzheimer's disease
JP6483711B2 (ja) * 2013-09-18 2019-03-13 ジョージタウン・ユニバーシティＧｅｏｒｇｅｔｏｗｎ Ｕｎｉｖｅｒｓｉｔｙ フェノフィブラート及びその類似体を用いた神経変性疾患の治療
WO2016061190A1 (en) * 2014-10-14 2016-04-21 The Board Of Trustees Of The Leland Stanford Junior University Method for treating neurodegenerative diseases
EP3892315A1 (en) * 2015-05-18 2021-10-13 The Board of Trustees of the Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
KR20180094989A (ko) * 2015-12-15 2018-08-24 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 주니어 유니버시티 노화 관련 인지장애 및 신경염증의 예방 및/또는 치료 방법
EP4171551A1 (en) * 2020-06-22 2023-05-03 Tranquis Therapeutics, Inc. Treatment of systemic immune activation syndromes

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4188486A (en) * 1976-12-07 1980-02-12 Kanebo, Ltd. 2-Substituted benzimidazole compounds
CN1395568A (zh) * 2000-01-14 2003-02-05 舍林股份公司 用于治疗与小胶质细胞活化有关的疾病的1,2－二芳基苯并咪唑衍生物
WO2003004023A1 (de) * 2001-07-06 2003-01-16 Schering Aktiengesellschaft 1-alkyl-2-aryl-benzimidazolderivate, deren verwendung zur herstellung von arzneimitteln sowie diese derivate enthaltende pharmazeutische präparate
CN1756546A (zh) * 2002-02-15 2006-04-05 舍林股份公司 用于阻断白细胞介素12和IFNγ介导的免疫反应的小胶质细胞抑制剂
WO2004000817A2 (en) * 2002-06-24 2003-12-31 Pfizer Products Inc. Benzimidazole compounds and their use as estrogen agonists/antagonists
CN101083985A (zh) * 2004-09-21 2007-12-05 幸讬制药公司 用于炎症及免疫相关用途的化合物
CN101142194A (zh) * 2005-03-14 2008-03-12 特兰斯泰克制药公司 吲哚衍生物，组合物及用作β-分泌酶抑制剂的方法
CN104873500A (zh) * 2015-04-29 2015-09-02 中国人民解放军第四军医大学 化合物zln005的用途

Also Published As

Publication number Publication date
RS61053B1 (sr) 2020-12-31
PT3390367T (pt) 2020-09-23
WO2017106050A1 (en) 2017-06-22
KR20180094989A (ko) 2018-08-24
MX2018007147A (es) 2019-03-28
IL259902B (en) 2021-08-31
US10653669B2 (en) 2020-05-19
MX379086B (es) 2025-03-10
EP3390367B1 (en) 2020-09-09
US20210059985A1 (en) 2021-03-04
IL285248B1 (en) 2025-06-01
US20180353474A1 (en) 2018-12-13
EP3390367A1 (en) 2018-10-24
JP2018537507A (ja) 2018-12-20
BR112018012195A2 (pt) 2018-12-18
SMT202000601T1 (it) 2021-01-05
HK1261918A1 (en) 2020-01-10
IL259902A (en) 2018-07-31
IL285248B2 (en) 2025-10-01
IL285248A (en) 2021-09-30
EP3741747C0 (en) 2024-10-16
CA3008019A1 (en) 2017-06-22
AU2016371598A1 (en) 2018-07-12
AU2016371598B2 (en) 2021-05-13
ES2830447T3 (es) 2021-06-03
DK3390367T3 (da) 2020-10-26
JP6837486B2 (ja) 2021-03-03
US20240245646A1 (en) 2024-07-25
HRP20201652T1 (hr) 2020-12-25
CN108884053A (zh) 2018-11-23
PL3390367T3 (pl) 2021-03-08
EP3390367A4 (en) 2019-08-07
EP3741747A1 (en) 2020-11-25
EP3741747B1 (en) 2024-10-16
HUE051771T2 (hu) 2021-03-29

Similar Documents

Publication Publication Date Title
CN108884053B (zh) 预防和/或治疗与衰老有关的认知障碍和神经炎症的方法
TWI280136B (en) Composition containing dipeptide of histidine and alanine for reducing uric acid
US9592217B2 (en) Method for treating skin inflammatory diseases
US20200170990A1 (en) Method for treating schnitzler's syndrome
WO2013184708A1 (en) Pharmaceutical composition for treating inflammation and pain
HK40041872A (en) Method for preventing and/or treating aging-associated cognitive impairment
US20240269104A1 (en) Method for treating parkinson's disease
HK1261918B (en) Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
BR112018012195B1 (pt) Uso de 2-[4-(1,1-dimetiletil)fenil]-1h-benzimidazol, ou um sal farmaceuticamente aceitável do mesmo

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant